Live Breaking News & Updates on Innovent biologics

Stay updated with breaking news from Innovent biologics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Innovent Receives Fast Track Designation from the U.S. FDA for IBI343 (TOPO1i anti-CLDN18.2 ADC) as Monotherapy for Advanced Pancreatic Cancer

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology. ....

China , Hui-zhou , Guangdong , Suzhou , Jiangsu , Adimab-incyte , Eli-lilly , Innovent-biologics , National-medical-products-administration , Prnewswire-innovent-biologics-inc , Linkedin , Md-anderson-cancer-center

Innovent to Present Multiple Clinical Study Results of Mazdutide at the ADA's 84th Scientific Sessions

/PRNewswire/ Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes. ....

United-states , Suzhou , Jiangsu , China , Peking , Beijing , American , Chinese , Adimab-incyte , Innovent-biologics , Eli-lilly , Linong-ji

CTLA-4 Inhibitors Pipeline Analysis 2024: EMA, PDMA, FDA Approvals, Clinical Trials, Therapies, Mechanism Of Action, Route Of Administration, And Comp...

....

United-states , Innovent-biologics , Bristol-myers-squibb , Akeso-biopharma , Drugs-under-different-phases-of-clinical-development , Pharmaceuticals-inc , Drug-administration , University-collaborations-licensing-partnering-analysis , Alpine-immune-sciences , Akeso-biopharma-co-ltd , Route-of-administration , Astrazeneca

Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib（ROS1 Inhibitor) are Published in the JCO and Reported at 2024 ASCO Annual Meeting

SAN FRANCISCO, U.S. and SUZHOU, China, June 2, 2024 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company… ....

China , Tongji , Sichuan , Suzhou , Jiangsu , Rhui-zhou , Guangdong , United-states , Hong-kong , Shanghai , Taiwan , Macau

Innovent Announces Data From Pivotal Phase 2 TRUST-I Study Of Taletrectinib(ROS1 Inhibitor) Are Published In The JCO And Reported At 2024 ASCO Annual ...

SAN FRANCISCO, U.S. and SUZHOU, China, June 1, 2024 /PRNewswire/ Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceut ....

Rhui-zhou , Guangdong , China , Tongji , Sichuan , Suzhou , Jiangsu , Shanghai , Hong-kong , Taiwan , Macau , United-states